175 related articles for article (PubMed ID: 26277279)
1. Metformin and cancer: Between the bioenergetic disturbances and the antifolate activity.
Jara JA; López-Muñoz R
Pharmacol Res; 2015 Nov; 101():102-8. PubMed ID: 26277279
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.
Corominas-Faja B; Quirantes-Piné R; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Martin-Castillo B; Micol V; Joven J; Segura-Carretero A; Menendez JA
Aging (Albany NY); 2012 Jul; 4(7):480-98. PubMed ID: 22837425
[TBL] [Abstract][Full Text] [Related]
3. Metformin and Breast Cancer: Molecular Targets.
Faria J; Negalha G; Azevedo A; Martel F
J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
[TBL] [Abstract][Full Text] [Related]
4. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
5. Metabolic switching in the hypoglycemic and antitumor effects of metformin on high glucose induced HepG2 cells.
Lv Y; Tian N; Wang J; Yang M; Kong L
J Pharm Biomed Anal; 2018 Jul; 156():153-162. PubMed ID: 29705631
[TBL] [Abstract][Full Text] [Related]
6. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
7. Metformin: from mechanisms of action to therapies.
Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
[TBL] [Abstract][Full Text] [Related]
8. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro.
Uehara T; Mitsuhashi A; Tsuruoka N; Shozu M
Oncol Rep; 2015 Feb; 33(2):744-50. PubMed ID: 25421433
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo anti-melanoma action of metformin.
Janjetovic K; Harhaji-Trajkovic L; Misirkic-Marjanovic M; Vucicevic L; Stevanovic D; Zogovic N; Sumarac-Dumanovic M; Micic D; Trajkovic V
Eur J Pharmacol; 2011 Oct; 668(3):373-82. PubMed ID: 21806981
[TBL] [Abstract][Full Text] [Related]
10. Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment.
Sui X; Xu Y; Wang X; Han W; Pan H; Xiao M
Mol Pharm; 2015 Nov; 12(11):3783-91. PubMed ID: 26430787
[TBL] [Abstract][Full Text] [Related]
11. Regulation of organelle function by metformin.
Kim J; You YJ
IUBMB Life; 2017 Jul; 69(7):459-469. PubMed ID: 28444922
[TBL] [Abstract][Full Text] [Related]
12. Metformin adapts its cellular effects to bioenergetic status in a model of metabolic dysfunction.
Auger C; Sivayoganathan T; Abdullahi A; Parousis A; Pang BW; Jeschke MG
Sci Rep; 2018 Apr; 8(1):5646. PubMed ID: 29618839
[TBL] [Abstract][Full Text] [Related]
13. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
Ben Sahra I; Regazzetti C; Robert G; Laurent K; Le Marchand-Brustel Y; Auberger P; Tanti JF; Giorgetti-Peraldi S; Bost F
Cancer Res; 2011 Jul; 71(13):4366-72. PubMed ID: 21540236
[TBL] [Abstract][Full Text] [Related]
14. Repositioning metformin for cancer prevention and treatment.
Quinn BJ; Kitagawa H; Memmott RM; Gills JJ; Dennis PA
Trends Endocrinol Metab; 2013 Sep; 24(9):469-80. PubMed ID: 23773243
[TBL] [Abstract][Full Text] [Related]
15. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt.
Janjetovic K; Vucicevic L; Misirkic M; Vilimanovich U; Tovilovic G; Zogovic N; Nikolic Z; Jovanovic S; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
Eur J Pharmacol; 2011 Jan; 651(1-3):41-50. PubMed ID: 21114978
[TBL] [Abstract][Full Text] [Related]
16. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
Gallagher EJ; LeRoith D
Ann N Y Acad Sci; 2011 Dec; 1243():54-68. PubMed ID: 22211893
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding The Anticancer Effect of Metformin and Its Clinical Implications.
Cazzaniga M; Bonanni B
Anticancer Res; 2015 Nov; 35(11):5789-96. PubMed ID: 26503999
[TBL] [Abstract][Full Text] [Related]
18. Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions?
Dogan Turacli I; Umudum H; Pampal A; Candar T; Kavasoglu L; Sari Y
Mol Biol Rep; 2018 Jun; 45(3):195-201. PubMed ID: 29397517
[TBL] [Abstract][Full Text] [Related]
19. A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate.
McCarty MF
Med Hypotheses; 1999 Feb; 52(2):89-93. PubMed ID: 10340287
[TBL] [Abstract][Full Text] [Related]
20. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
